Optimizing Glycemic Control in T2DM Patients Previously Treated With Intensive Insulin Therapy and Switched to Exenatide-Insulin Glargine Combination

被引：0
|
作者：
Avramidis, Iakovos
Spyridonidou, Christina
Stoimenis, Dimitris
Lalia, Antigoni
机构：
来源：
DIABETES | 2013年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1017-P
引用
收藏
页码：A261 / A261
页数：1
相关论文
共 50 条
  • [31] Comparison of the Effects of Insulin Detemir (IDet) and Insulin Glargine (IGlar) in Patients With Type 2 Diabetes (T2DM) in Turkey
    Damci, Taner
    Emral, Rifat
    Svendsen, Anne Louise
    Balkir, Tanzer
    Vora, Jiten
    [J]. DIABETES, 2013, 62 : A653 - A653
  • [32] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The Lixi-Lan-L Trial
    Aroda, Vanita
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Galvez, Guillermo Gonzalez
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    [J]. DIABETES, 2016, 65 : A62 - A63
  • [33] Benefit-Risk Relationship between A1C and Hypoglycemia for Addition of Exenatide BID to Insulin Glargine in Patients with T2DM
    Malloy, Jaret
    Zhou, Ming
    Han, Jenny
    [J]. DIABETES, 2014, 63 : A103 - A103
  • [34] Glycemic Outcomes Following Initiation of Insulin Glargine or Exenatide in Patients with Type 2 Diabetes
    Rosenstock, Julio
    Daine, Marie-Paule
    Bhushan, Madhu
    Bhushan, Rajat
    Home, Philip
    [J]. DIABETES, 2009, 58 : A137 - A138
  • [35] Local Tolerability of Insulin Degludec is Comparable to Insulin Glargine: A Meta-Analysis of T1DM and T2DM
    Meneghini, Luigi F.
    Schumm-Draeger, Petra-Maria
    Harris, Stewart
    Gall, Mari-Anne
    Lassota, Nathan
    Christiansen, Jens S.
    [J]. DIABETES, 2012, 61 : A230 - A230
  • [36] Pharmacist-led diabetes collaborative drug therapy management program improves glycemic control in patients with uncontrolled T2DM treated with insulin.
    McAdam-Marx, Carrie
    Jennings, Brandon T.
    Dahal, Arati
    Gunning, Karen
    [J]. PHARMACOTHERAPY, 2012, 32 (10): : E261 - E261
  • [37] Switching to Insulin Degludec Improves Glycemic Control in Patients with T2DM in a Real-World Setting
    Schultes, Bernd
    Tentolouris, Nikolaos
    Knudsen, Soren T.
    Lapolla, Annunziata
    Eidenmueller, Markus
    Prager, Rudolf
    Phan, Tra-Mi
    Wolden, Michael L.
    Siegmund, Thorsten
    [J]. DIABETES, 2017, 66 : A266 - A266
  • [38] Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy
    Karagianni, P.
    Polyzos, S. A.
    Kartali, N.
    Zografou, I
    Sambanis, C.
    [J]. ADVANCES IN MEDICAL SCIENCES, 2013, 58 (01): : 38 - 43
  • [39] Impact of Insulin Glargine on Glycemic Control and Hypoglycemia in Patients With Type 1 Diabetes Previously Treated With Other Insulins
    Chase, Peter
    Lin, Jay
    Wei, Wenhui
    Cali, Anna
    Dailey, George
    [J]. DIABETES, 2013, 62 : A650 - A650
  • [40] iGlarLixi Fixed-Ratio Combination vs. Insulin Glargine and Lixisenatide in Patients with T2DM Treated Previously with Two Oral Antidiabetics: LixiLan-O Subgroup Analysis
    Russell-Jones, David
    Mccrimmon, Rory J.
    Barber, Thomas M.
    Baradez, Cecile
    Baxter, Michael A.
    Davies, Melanie
    [J]. DIABETES, 2017, 66 : LB35 - LB35
12345